Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:52pm CET

Aspen yesterday welcomed the Competition Commission`s decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commissions initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany, the commission said.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Valeurs citées dans l'article
ChangeLast1st jan.
PFIZER -0.69% 36.01 Delayed Quote.-2.84%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
11:12aTAKEDA PHARMACEUTICAL : Organ-on-chip company Emulate reveals new deals
09:18aQUOTIENT LIMITED : Announces Appointment of Franz Walt as Non-Executive Director
09:16aROCHE : Emulate, Inc. Announces Strategic Partnership with Leading Pharmaceutica..
02/19ROCHE : Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, an..
02/19ROCHE : Clifton sees increase in its tax base
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
02/18ROCHE : Ex-Googlers Strike Startup Gold Again With $1.9 Billion Sale
02/16ROCHE : Diagnostics recognizes Wisconsin Diagnostic Laboratories as Roche Molecu..
02/16ROCHE : LGC Maine Standards Announces VALIDATE Procalcitonin Kit for Easier Line..
02/16ROCHE : Slump ends and city sees tax base increase
More news
News from SeekingAlpha
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16Roche To Acquire Flatiron Health For $1.9 Billion 
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
02/16Key events next week - healthcare 
02/16'Intense' flu season to continue 
Financials ( CHF)
Sales 2018 55 281 M
EBIT 2018 18 795 M
Net income 2018 12 313 M
Debt 2018 4 043 M
Yield 2018 3,92%
P/E ratio 2018 15,41
P/E ratio 2019 14,83
EV / Sales 2018 3,60x
EV / Sales 2019 3,46x
Capitalization 195 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 268  CHF
Spread / Average Target 20%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.37%207 826
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%133 241